Everything below concerns peptide purity. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilised powder | Reconstitution is required before use in most assays |
| Solubility class | Freely soluble in water and acetonitrile; sparingly soluble in nonpolar solvents | Aqueous solutions may benefit from slight acidification |
| Typical storage temperature | -20 °C or lower, desiccated and protected from light | Short-term transport at 2-8 °C is common practice |
| Primary degradation routes | Oxidation, hydrolysis, aggregation | Tryptophan and histidine residues are the main oxidation targets |
| Quality marker | Chromatographic purity by peak area | Does not capture counter-ion content or residual solvents |
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
=== Acid dissolution === Acids can be used to learn more about fossil eggs. Diluted acetic acid or EDTA can be used to expose the microstructure of shell that has been damaged by weathering. Acids are also used to extract embryo skeletons from the egg encasing them. Even fossilized soft tissue like muscle and cartilage as well as fat globules from the original egg yolk can be uncovered using this method. Amateur paleontologist Terry Manning has been credited with groundbreaking work developing this technique. First, the paleontologist must submerge the egg in a very dilute phosphoric acid bath. Since the acid solution can penetrate the egg, every few days the specimen must be soaked in distilled water to prevent the acid from damaging the embryo before it is even exposed. If embryonic fossil bone is revealed after drying from the water bath, the exposed fossils must be delicately cleaned with fine instruments like needles and paint brushes. The exposed bone is then coated with plastic preservatives like Acryloid B67, Paraloid B72, or Vinac B15 to protect it from the acid when submerged for another round. The complete process can take months before the whole embryo is revealed. Even then only about 20% of the eggs subjected to the process reveal any embryo fossils at all.
In early 1947, France, Britain and the United States unsuccessfully attempted to reach an agreement with the Soviet Union for a plan envisioning an economically self-sufficient Germany, including a detailed accounting of the industrial plants, goods and infrastructure already taken by the Soviets. In June 1947, in accordance with the Truman Doctrine, the United States enacted the Marshall Plan, a pledge of economic assistance for all European countries willing to participate. Under the plan, which President Harry S. Truman signed on 3 April 1948, the US government gave to Western European countries over $13 billion (equivalent to $189 billion in 2016). Later, the program led to the creation of the OECD. The plan's aim was to rebuild the democratic and economic systems of Europe and to counter perceived threats to the European balance of power, such as communist parties seizing control. The plan also stated that European prosperity was contingent upon German economic recovery. One month later, Truman signed the National Security Act of 1947, creating a unified Department of Defense, the Central Intelligence Agency (CIA), and the National Security Council (NSC). These would become the main bureaucracies for US defense policy in the Cold War. Stalin believed economic integration with the West would allow Eastern Bloc countries to escape Soviet control, and that the US was trying to buy a pro-US re-alignment of Europe. Stalin therefore prevented Eastern Bloc nations from receiving Marshall Plan aid.
==== Ohio jury trial ==== In October 2021, a landmark trial began in a Cleveland court. The defendants are pharmacy chains and operators, including Walmart, Walgreens and CVS. These chains are accused of not having enough trained staff and sophisticated systems to responsibly dispense opioids. Lawyers allege that pharmacies have not fulfilled their legal responsibility to act as a "last line of defense," and that the chains enable illegal street dealing of prescription opioids. Lake and Trumbull Counties in northeast Ohio were the plaintiffs and alleged the chains had "substantially contributed to the crisis of opioid overdose and deaths…." in the counties. In November 2021, a 12-person jury, after five and a half days of deliberation, held the retailers accountable for contributing to a "public nuisance." This was the first jury verdict in the decades-long crisis. The retailers said they would appeal the jury's verdict. On August 17, 2022, CVS, Walgreens and Walmart were forced to pay out $650.5 million to Lake and Trumbull County.
Sources: en.wikipedia.org
=== Rare human diseases === Mutations in TERT have been implicated in predisposing patients to aplastic anemia, a disorder in which the bone marrow fails to produce blood cells, in 2005. Cri du chat syndrome (CdCS) is a complex disorder involving the loss of the distal portion of the short arm of chromosome 5. TERT is located in the deleted region, and loss of one copy of TERT has been suggested as a cause or contributing factor of this disease. Dyskeratosis congenita (DC) is a disease of the bone marrow that can be caused by some mutations in the telomerase subunits. In the DC cases, about 35% cases are X-linked-recessive on the DKC1 locus and 5% cases are autosomal dominant on the TERT and TERC loci. Patients with DC have severe bone marrow failure manifesting as abnormal skin pigmentation, leucoplakia (a white thickening of the oral mucosa) and nail dystrophy, as well as a variety of other symptoms. Individuals with either TERC or DKC1 mutations have shorter telomeres and defective telomerase activity in vitro versus other individuals of the same age. In one family autosomal dominant DC was linked to a heterozygous TERT mutation. These patients also exhibited an increased rate of telomere-shortening, and genetic anticipation (i.e., the DC phenotype worsened with each generation).
== Distribution and habitat == N. christyi has a small geographic range. It occurs in western Democratic Republic of Congo, the southern half of the Republic of Congo, a very small portion of southeastern Gabon, and in the province of Cabinda in far northern Angola. N. christyi is found most commonly in or near water, in lowland bushy or wooded areas along banks of lakes, rivers, and streams. It is limited to the lower Congo River and nearby wet forested areas.
In Switzerland, institutionalized radiation protection began in 1955 with the issuance of guidelines for protection against ionizing radiation in medicine, laboratories, industry and manufacturing plants, although these were only recommendations. The legal basis was created by a new constitutional article (Art. 24), according to which the federal government issues regulations on protection against the dangers of ionizing radiation. On this basis, a corresponding federal law entered into force on July 1, 1960. The first Swiss ordinance on radiation protection entered into force on May 1, 1963. On October 7, 1963, the Federal Department of Home Affairs (EDI) issued the following decrees to supplement the ordinance:
=== High Voltage Power Corporation === In July 1968, High Voltage Engineering Corporation and Reynolds Metals Company announced they would form a joint venture partnership to develop, produce, and sell gas-insulated systems for transmission of electric power. The venture, High Voltage Power Corporation, aimed to commercialize technology for underground electric power transmission. HVEC president Denis Robinson noted increasing need by bury transmission lines underground for technological, economic, and aesthetic reasons, and emphasizing that compressed gas offered unique advantages for transmitting large amounts of power at high voltages with increased reliability at lower cost. Each company held a 50% interest in the venture, with Reynolds providing funds and technical research while HVEC contributed its patents, licenses, and know-how. The development work was carried out at HVEC's Burlington factory. The subsidiary's products included insulating-core reactors for nuclear power plants and gas-insulated transmission systems for electrical utilities, based on Van de Graaff's insulating-core transformer invention. However, by 1974, High Voltage Power Corp. losses were consuming 60-75% of HVEC's cash flow despite generating only $1.5-2 million in annual sales, leading HVEC to divest from the subsidiary.
Sources: en.wikipedia.org
Solutions are best kept cold, protected from light, and buffered to a pH that limits hydrolysis. Dividing a stock into single-use aliquots avoids repeated freeze-thaw cycles, which measurably reduce the intact parent peak over time.
Reversed-phase chromatography establishes a purity profile, while electrospray or matrix-assisted laser desorption mass spectrometry confirms that the observed mass matches the expected sequence. Together they support, but do not fully prove, identity and purity.
Reviews generally characterise it as thin, dominated by small and often uncontrolled studies. Several authors explicitly note that findings on pigmentation, appetite and sexual function have not been confirmed in adequately powered controlled trials.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.